In this analysis of 6,000+ real-world metastatic ER+ or PR+ and HER2+ breast cancer patients, we identified two distinct first-line treatment patterns: hormonal therapy and chemotherapy. The gene discussed is ERBB2; the disease is breast carcinoma.